Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
从赛诺菲收购的宏碁治疗产品在更年期研究中失败
- Acer Therapeutics Inc (NASDAQ:ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.
- The study showed that ACER-801 was safe and well-tolerated but did not achieve statistical significance when evaluating ACER-801's ability to decrease the frequency or severity of hot flashes in postmenopausal women.
- Related: Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder.
- Hence, Acer is pausing the ACER-801 program until Acer has thoroughly reviewed the full data set.
- Acer is continuing to focus on preparation for its commercial launch of OLPRUVA (sodium phenylbutyrate) for urea cycle disorders and the ongoing Phase 3 trial of EDSIVO (celiprolol) for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, subject to availability of additional capital beyond early in Q2 2023.
- In December 2018, Acer entered into an exclusive license agreement with Sanofi SA (NASDAQ:SNY) to acquire worldwide rights to ACER-801 (osanetant).
- Price Action: ACER shares are down 39.96% at $0.9306 on the last check Friday.
- Acer Therapeutics Inc (NASDAQ:ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.
- The study showed that ACER-801 was safe and well-tolerated but did not achieve statistical significance when evaluating ACER-801's ability to decrease the frequency or severity of hot flashes in postmenopausal women.
- Related: Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder.
- Hence, Acer is pausing the ACER-801 program until Acer has thoroughly reviewed the full data set.
- Acer is continuing to focus on preparation for its commercial launch of OLPRUVA (sodium phenylbutyrate) for urea cycle disorders and the ongoing Phase 3 trial of EDSIVO (celiprolol) for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, subject to availability of additional capital beyond early in Q2 2023.
- In December 2018, Acer entered into an exclusive license agreement with Sanofi SA (NASDAQ:SNY) to acquire worldwide rights to ACER-801 (osanetant).
- Price Action: ACER shares are down 39.96% at $0.9306 on the last check Friday.
- 宏碁 Therapeutics 纳斯达克股票代码：ACER）公布了其2a期概念验证临床试验的主要结果，该试验旨在评估 ACER-801（osanetant）作为与更年期相关的中度至重度血管舒缩症状（VMS）的潜在治疗方法。
- 该研究表明，ACER-801 安全且耐受性良好，但在评估 ACER-801 降低绝经后女性潮热频率或严重程度的能力时，并未达到统计学意义。
- 相关： Acer Therapeutics 将 ACER-801 的开发扩展到创伤后应激障碍。
- 因此，宏碁将暂停 ACER-801 程序，直到宏碁彻底审查了完整的数据集。
- 宏碁继续专注于为其治疗尿素循环障碍的OLPRUVA（苯丁酸钠）的商业发布以及正在进行的针对III型胶原蛋白突变确诊患者的EDSIVO（西立洛尔）的3期试验做准备，前提是2023年第二季度初以后的额外资金可用性。
- 2018 年 12 月，宏碁与 Acer 签订了独家许可协议 Sanofi SA 纳斯达克股票代码：SNY）将收购 ACER-801（osanetant）的全球版权。
- 价格走势： 周五的最后一张支票中，宏碁股价下跌39.96％，至0.9306美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！